Release date: 2015-12-09
On December 4th, the host Zhu Dan appeared at Peking University as a lecture. Originally, he wanted to share his experience with the North University. He did not expect that the scene was a few words, forgotten, and he was out of control and had to apologize to the audience. I admit that I really can't do it. She revealed that she would bid farewell to the stage because she had suffered from depression. For a time, the term depression became a hot search for the Internet, which triggered widespread concern in society.
In fact, depression, as a "by-product" of the fast-growing modern economy, has increasingly affected people's lives. According to relevant reports, depression has become the fourth largest disease in the world. By 2020, depression may become the second largest disease after heart disease. From the perspective of the national pharmaceutical market, although the overall size of the antidepressant drug market is still small, with the increase in the recognition rate of depression among doctors and the change in people's concept of visiting, businesses have taken a fancy to this market. It is foreseeable that the potential of the future antidepressant market will be quite large.
According to the 39 Health Network editors, in foreign countries, the total sales of depression and anxiety drugs accounted for 45% of the central nervous drug market share, while the combination of depression and schizophrenia treatments accounted for 80% of the world's psychotropic drugs. The total number of antidepressant drugs that have been marketed or under development ranges from 50 to 60, and the number has exceeded that of schizophrenia. According to reports, the world's best-selling eight antidepressants are fluoxetine, paroxetine, sertraline, fluvoxamine, venlafaxine, mirtazapine, duloxetine and amitriptyline. Sales exceed 80% of the global antidepressant market.
Data show that from 2010 to 2014, China's antidepressant market sales increased from 2.51 billion yuan to 4.78 billion yuan. However, China's antidepressants face the reality that there are fewer varieties of fists and more imitations. The data shows that the top 5 domestic products account for 64% of the market share. Among the 30 varieties that are listed abroad and not listed in China, 5 have already been declared, but there are still 25 varieties that have no enterprise declaration.
Therefore, the anti-depression original Chinese medicine, Yi Xinding, which has been developed in the past 10 years, has received much attention. This is the first in China to receive clinical trial approval and the first clinical trial research in the field of neuro-theology, and won the domestic first-class innovative new drug supported by the 11th Five-Year Plan and the 12th Five-Year National New Drug Creation Fund. It is possible that in the near future, the embarrassing situation in which only western medicine can be taken by patients with depression can be broken, and its social and economic value cannot be underestimated.
Yang Zirong, director of the Shanghai Chinese Medicine Innovation Research Center, said in an interview with 39 Health Net editors, "Youxinding is independently developed by Shanghai Traditional Chinese Medicine Innovation Research Center and has independent intellectual property rights including its process and application patents. Its patent scope covers China, The United States, Germany, France, the United Kingdom, Italy, Sweden, Japan and South Korea, etc."
"The development of Youxinding is derived from the traditional Chinese medicine ginseng. Its active ingredient is a metabolite produced in the body after oral administration. The metabolite is produced by using ginseng plants as raw materials to obtain high-purity single-molecular raw materials through hydrolysis and other innovative processes. "Yang Zirong introduced that Yuxinding Capsule has the advantages of high safety, less toxic side effects and lower cost, as well as clear chemical ingredients, remarkable efficacy, novel mechanism and consistent quality control. A new drug that is very difficult to find and has both the characteristics and advantages of Chinese and Western medicine.
It is understood that Shanghai Traditional Chinese Medicine Innovation Research Center has been committed to the research and development of innovative drugs since its establishment. At present, it has obtained 2 clinical trials for drugs, 1 Chinese medicine for overseas listing, 3 new drugs for pre-clinical category, and more than 60 invention patents. Among them, 25 international patents.
At the policy level, antidepressants are also welcoming. In June this year, the National Mental Health Work Plan (2015~2020) jointly issued by the Health Planning Commission and other departments mentioned that the treatment rate of depression in China has increased by 50% on the existing basis, and depression is common in all places. In the prevention and treatment of mental disorders, China will establish and improve three-level mental health institutions in provinces, cities and counties in the next five years, and more than 70% of the counties have mental rehabilitation institutions.
The annual sales of global depression drugs are more than two billion dollars, and such a large cake is divided by Western companies' chemical drugs. If Youxin will be able to successfully list, it will not only break the monopoly of foreign products, but also make the innovative Chinese medicine have a place in the international pharmaceutical arena. It will also provide an important reference for the innovation and research of traditional Chinese medicine.
Source: 39 Health Net
Dehydrated Coriander,Dehydrated Coriander For Seasoning,Dehydrated Coriander For Cooking,Dehydrated Coriander Powder
Xinghua Lvwei Foods Co.,Ltd , https://www.lvweifoods.com